Castle Biosciences Inc
NASDAQ:CSTL

Watchlist Manager
Castle Biosciences Inc Logo
Castle Biosciences Inc
NASDAQ:CSTL
Watchlist
Price: 26.83 USD -1% Market Closed
Market Cap: 751.5m USD
Have any thoughts about
Castle Biosciences Inc?
Write Note

Castle Biosciences Inc
Total Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Castle Biosciences Inc
Total Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Assets CAGR 3Y CAGR 5Y CAGR 10Y
Castle Biosciences Inc
NASDAQ:CSTL
Total Assets
$514.6m
CAGR 3-Years
6%
CAGR 5-Years
35%
CAGR 10-Years
N/A
Quest Diagnostics Inc
NYSE:DGX
Total Assets
$16.1B
CAGR 3-Years
6%
CAGR 5-Years
6%
CAGR 10-Years
5%
CVS Health Corp
NYSE:CVS
Total Assets
$252.4B
CAGR 3-Years
2%
CAGR 5-Years
3%
CAGR 10-Years
13%
Cigna Corp
NYSE:CI
Total Assets
$157.6B
CAGR 3-Years
1%
CAGR 5-Years
0%
CAGR 10-Years
11%
Laboratory Corporation of America Holdings
NYSE:LH
Total Assets
$18.6B
CAGR 3-Years
-4%
CAGR 5-Years
1%
CAGR 10-Years
10%
R1 RCM Inc
NASDAQ:RCM
Total Assets
$5.7B
CAGR 3-Years
57%
CAGR 5-Years
45%
CAGR 10-Years
28%
No Stocks Found

Castle Biosciences Inc
Glance View

Market Cap
750.6m USD
Industry
Health Care

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company is headquartered in Friendswood, Texas and currently employs 342 full-time employees. The company went IPO on 2019-07-25. The company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. The firm markets five multi-analyte assays with algorithmic analysis (MAAA) tests for use in the dermatologic, ocular and gastroenterology fields: DecisionDx-Melanoma, DecisionDx-SCC, Comprehensive Diagnostic Offering (CDO), DecisionDx-UM and TissueCypher Barrett’s Esophagus Assay. DecisionDx-Melanoma is risk stratification gene expression profile (GEP) test developed to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. DecisionDx-SCC, a 40-gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of squamous cell carcinoma (SCC) metastasis for patients with one or more risk factors.

CSTL Intrinsic Value
15.6 USD
Overvaluation 42%
Intrinsic Value
Price

See Also

What is Castle Biosciences Inc's Total Assets?
Total Assets
514.6m USD

Based on the financial report for Sep 30, 2024, Castle Biosciences Inc's Total Assets amounts to 514.6m USD.

What is Castle Biosciences Inc's Total Assets growth rate?
Total Assets CAGR 5Y
35%

Over the last year, the Total Assets growth was 18%. The average annual Total Assets growth rates for Castle Biosciences Inc have been 6% over the past three years , 35% over the past five years .

Back to Top